Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
Citrullinated myelin basic protein (citMBP) is a citrullinated form of MBP, a protein that is integral to myelin stability in the CNS.{42873} MBP contains 19 arginine residues that can be citrullinated by peptidylarginine deiminases (PADs), decreasing the positive charge of MBP.{42873,42874} The loss of positive charge disrupts MBP-lipid interactions, leading to myelin destabilization and loss and increases its susceptibility for degradation. MBP is degraded by the myelin-associated protease cathepsin D, which leads to exposure and release of immunodominant epitopes.{42873,42875} The percentage of MBP that is citrullinated is increased in the postmortem brain from patients with multiple sclerosis (MS), with an even greater percentage citrullinated in Marburg disease, a more severe form of MS.{42873} citMBP isolated from patients with multiple sclerosis (MS) is degraded by cathepsin D at a higher rate than MBP isolated from healthy controls.{42873,42875} Cayman’s Citrullinated Myelin Basic Protein (R122) Monoclonal Antibody (Clone 1H1) can be used for ELISA, immunohistochemistry (IHC), and Western blot applications. The antibody recognizes citMBP from human and mouse samples and was generated using a peptide immunogen containing citrulline at R122 (human myelin basic protein sequence, isoform 5).
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.